typically refers to a specific Panasonic WhisperCeiling ventilation fan model, which is a powerful yet quiet exhaust fan commonly used in bathrooms and laundry rooms. Ubuy France Panasonic WhisperCeiling (1.3 Sone, 190 CFM)
This "piece" of equipment is designed for large bathrooms and light commercial applications where high airflow is needed without excessive noise. Model Number : Often listed as Performance
: 190 CFM (Cubic Feet per Minute), capable of moving a large volume of air quickly. Noise Level : Operates at , which is considered very quiet for a fan of this power. Key Features Energy Star Certified : Meets strict energy efficiency guidelines.
: Features a totally enclosed condenser motor and double-tapered blower wheel for longevity and quietness. Construction
: Heavy-gauge zinc galvanized steel housing to prevent rust. : Large bathrooms (up to 190 sq ft), garages, or basements. Ubuy Madagascar SONE-190
Panasonic WhisperCeiling Bathroom Exhaust Fan, 190 Madagascar
Feature: SONE‑190 – A New Hope on the Horizon for Neuro‑Degenerative Disease
By [Your Name], Science & Medicine Correspondent
April 16, 2026
The molecule belongs to a novel chemotype of spiro‑cyclopropane‑based inhibitors. Key attributes include: chronic traumatic encephalopathy
| Property | Value (Pre‑clinical) | |----------|----------------------| | Molecular weight | 378 Da | | LogP | 2.1 (balanced lipophilicity) | | Brain/plasma ratio (rat) | 1.3 | | Oral bioavailability | ~65% | | Half‑life (human) | 12 h (dose‑proportional) |
These characteristics give SONE‑190 good oral exposure and robust CNS penetration, a combination that has eluded many past attempts at targeting TDP‑43.
Dr. Elena Martínez, Neurologist, University of Barcelona
“For years we have watched patients with FTD decline inexorably, with only symptomatic support to offer. The ability of SONE‑190 to lower CSF pTDP‑43 is the first sign we’ve seen that a disease‑modifying effect may be achievable.” Implementation Tradeoffs & Mitigations
Dr. Aaron Patel, Chief Scientific Officer, Sone Therapeutics
“Our team leveraged a combination of AI‑driven pocket detection and traditional medicinal chemistry. The spiro‑cyclopropane scaffold was a surprise win; it gave us the right balance of brain exposure and selectivity.”
Dr. Linda Zhao, FDA Deputy Center Director, Neurology
“The Fast Track grant reflects both the unmet medical need in FTD and the rigor of the data package submitted. We’ll be watching the upcoming Phase 2a closely, particularly the adaptive biomarker endpoints.”
If SONE‑190 continues its upward trajectory, it could redefine therapeutic strategy for TDP‑43 proteinopathies—not only FTD but also ALS, chronic traumatic encephalopathy, and certain forms of Alzheimer's disease where TDP‑43 pathology co‑occurs. The drug’s oral route also opens the door to combination trials, pairing it with antisense therapies that target upstream genetic drivers.
In the broader picture, SONE‑190 exemplifies a new paradigm: leveraging structural biology and AI to discover allosteric sites on intrinsically disordered proteins—a class once considered “undruggable.” Success here could spark a cascade of similar programs across neuro‑degeneration.
No products in the cart.